Title:Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis
Volume: 9
Issue: 2
Author(s): Rashi Chauhan, Gulshan Wadhwa, Sanjeev K. Sharma and Chakresh K. Jain
Affiliation:
Keywords:
Antibodies, Coxiella burnetii, doxycycline, fluoroquinolone, therapeutics, vaccines.
Abstract: Coxiella burnetii is an infectious and etiological agent responsible for causing Q fever. There are mainly two
forms of the Q fever that are chronic and acute. Though the acute type is usually linked with symptoms like pneumonia
and hepatitis, the chronic form is shown to have mortality rate of 5%. Percentage of mortality rate might increases from
5% to 25% if left untreated. The present treatments of disease include the recommended dose of drugs and vaccine. Presently,
extensive attempt is in progress to find novel therapies to combat the disease. This review is projected to provide a
brief introduction of C. burnetii and Q fever while emphasizing therapeutics, prophylactic measures and diagnostic applications
based on recent patents prospects.
